Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate in Binge-Eating Disorder Associated With Obesity
NCT00210808Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in binge eating disorder (BED) comparing Topiramate with Placebo (2 arms). Primary endpoint: Rate of change in the number of binge days per week at 16 weeks. Started Sep 2003; status: completed.
02
Drugs
topiramate
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT00210808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210808.